Study of MLN4924 in Adult Patients With Nonhematologic Malignancies
This study is an open-label, multicenter, Phase 1, dose escalation study of MLN4924 in adult patients with nonhematologic malignancies. This study will be the first to administer MLN4924 in humans. The patient population will consist of adults with any form of nonhematologic malignancy for which standard, curative, life prolonging, or palliative treatment does not exist or is no longer effective.
Advanced Nonhematologic Malignancies
DRUG: MLN4924
Determine the safety profile, MTD and PK/pharmacodynamics of MLN4924, Maximum duration of therapy for 12 months
Disease response, Day 21, every other cycle and end of study
This study is an open-label, multicenter, Phase 1, dose escalation study of MLN4924 in adult patients with nonhematologic malignancies. This study will be the first to administer MLN4924 in humans. The patient population will consist of adults with any form of nonhematologic malignancy for which standard, curative, life prolonging, or palliative treatment does not exist or is no longer effective.